Jan Štraub
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
-
- Peptidase Inhibition and Analysis
Papers in
- Hematology 32
- Multiple Myeloma Research and Treatments 29
- Oncology 25
- Cancer Treatment and Pharmacology 12
- Peptidase Inhibition and Analysis 11
- Co-authors
- Ivan Špıčka (17 shared papers)Fernando F. Illescas (1 shared paper)Steven K. Sussman (1 shared paper)Michael J. Hallisey (1 shared paper)Hugh S. Vine (1 shared paper)Rune R. Frants (1 shared paper)H.P.M. Festen (1 shared paper)J. Défize (1 shared paper)
- Journals
- Blood (8 papers)British Journal of Haematology (2 papers)Biomedicines (2 papers)Annals of Hematology (2 papers)HemaSphere (2 papers)
- Partner nations
- CzechiaUnited StatesSpain
In The Last Decade
Jan Štraub
35 papers receiving 315 citations
Peers
Comparison fields: 5 of 49
- Hematology 163
- Oncology 104
- Genetics 36
- Pulmonary and Respiratory Medicine 96
- Nephrology 18
Countries citing papers authored by Jan Štraub
This map shows the geographic impact of Jan Štraub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Štraub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Štraub more than expected).
Fields of papers citing papers by Jan Štraub
This network shows the impact of papers produced by Jan Štraub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Štraub. The network helps show where Jan Štraub may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan Štraub, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1995 | 65 | |
| 2 | 1986 | 41 | |
| 3 | 2012 | 37 | |
| 4 | 2017 | 28 | |
| 5 | 2010 | 23 | |
| 6 | 2015 | 21 | |
| 7 | 2020 | 15 | |
| 8 | 2021 | 11 | |
| 9 | 2012 | 11 | |
| 10 | 2015 | 10 | |
| 11 | 2020 | 8 | |
| 12 | 2023 | 6 | |
| 13 | 2022 | 5 | |
| 14 | 2023 | 5 | |
| 15 | [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma]. | 1996 | 5 |
| 16 | 2022 | 4 | |
| 17 | 2018 | 4 | |
| 18 | [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]. | 2005 | 4 |
| 19 | [Mixed myelodysplastic and myeloproliferative syndromes]. | 1997 | 4 |
| 20 | 2024 | 3 |
About Jan Štraub
Jan Štraub is a scholar working on Hematology, Oncology, Molecular Biology, Pathology and Forensic Medicine and Surgery, having authored 39 papers that have together received 332 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (16 papers), Cancer Treatment and Pharmacology (12 papers), Peptidase Inhibition and Analysis (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (3 papers), Phytochemical compounds biological activities (2 papers) and Hematological disorders and diagnostics (2 papers). The work is most often cited by research in Hematology (163 citations), Oncology (104 citations), Genetics (36 citations), Pulmonary and Respiratory Medicine (96 citations) and Nephrology (18 citations). Jan Štraub has collaborated with scholars based in Czechia, United States and Spain. Frequent co-authors include Ivan Špıčka, Fernando F. Illescas, Steven K. Sussman, Michael J. Hallisey, Hugh S. Vine, Rune R. Frants, H.P.M. Festen, J. Défize, S. G. M. Meuwissen and Roman Hájek. Their work appears in journals such as Blood, British Journal of Haematology, Biomedicines, Annals of Hematology and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.